Liminatus Pharma Regains Nasdaq Bid-Price Compliance After Reverse Split

What Happened
Liminatus Pharma, Inc. (LIMN) filed an 8‑K on September 29, 2026 announcing it has regained compliance with Nasdaq’s minimum bid-price requirement. After receiving a Nasdaq notice on January 15, 2026 and being transferred to The Nasdaq Capital Market effective August 4, 2026, the company effected a 1‑for‑50 reverse stock split at the close of trading on August 20, 2026. Nasdaq notified the company on September 24, 2026 that the closing bid price exceeded $1.00 for 13 consecutive trading days (August 21–September 9, 2026), and therefore the company is back in compliance and the matter is closed.

Key Details

• Nasdaq non‑compliance notice initially received January 15, 2026 for closing bid below $1.00 for 30 consecutive business days.
• Nasdaq Hearings Panel transferred the company to The Nasdaq Capital Market effective August 4, 2026 and gave an extension to comply with the Bid Price Rule.
• Liminatus implemented a 1‑for‑50 reverse stock split at market close on August 20, 2026.
• Nasdaq confirmed on September 24, 2026 that the closing bid exceeded $1.00 for 13 consecutive trading days (Aug 21–Sep 9, 2026); company regained compliance.

Why It Matters
Regaining compliance preserves Liminatus’s Nasdaq listing and avoids potential delisting actions tied to the minimum bid-price rule, which is important for shareholder liquidity and continued access to capital markets. The reverse split changed the share count and nominal per‑share price, which can affect trading dynamics and per‑share metrics; the filing does not report operational results or other financial changes. Investors should note the company announced the development by press release on September 29, 2026 and may monitor trading, outstanding share count, and future filings for further corporate or financial updates.